Agilent Technologies and Bia Separations have announced the signing of an agreement that gives Agilent access to Bia Separations's bio-monolithic technology
Agilent plans to commercialise analytical HPLC bio-monolith columns with strong and weak ion-exchange phases and a Protein A phase.
BIA Separations currently provides their preparative scale CIM disk and process scale CIM tube bio-monolithic products for purification and bioconversion of bio-molecules.
"Having access to the bio-monolithic technology allows Agilent to provide enabling solutions for the analytical separation of virus particles, plasmid DNA, antibodies and other macro bio-molecules," said Helen Stimson, vice president and general manager of Agilent's global columns and supplies.
"This technology, when applied at the analytical scale, will improve bio-drug characterisation in development and allow QA/QC and process control labs to better monitor and characterise the production of biologics".
Bia Separations's bio-monolithic technology is a revolutionary chromatographic and bioconversion support based on a highly cross-linked porous monolithic polymer.
Due to a well-defined pore-size distribution, the monolith provides excellent separation power and efficiency.
The support is characterised by flow-independent, high-resolution separations and a flow-independent binding capacity.
It can be operated at very high flow rates, significantly decreasing the separation time of large bio-molecules.
"The partnership between Agilent and Bia Separations will make the bio- monolithic technology available to the analytical bio-chromatography market and will allow Bia Separations to focus its marketing and sales activities on preparative and process scale bio-chromatography applications," said Ales Strancar, Bia Separations managing director and co-inventor of CIM monolithic column technology.
"Bia Separations is currently offering enabling and cost-effective purification solutions for large bio-molecules and nano-particles like IgM, plasmid DNA, vaccines, viral vectors and phages at the industrial scale."
